Stoke Therapeutics Gestion
Gestion contrôle des critères 1/4
Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.
Informations clés
Ian Smith
Directeur général
US$27.0m
Rémunération totale
| Pourcentage du salaire du PDG | 0.63% |
| Durée du mandat du directeur général | 1.2yrs |
| Propriété du PDG | n/a |
| Durée moyenne d'occupation des postes de direction | 1.3yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 7.3yrs |
Mises à jour récentes de la gestion
Recent updates
Article d’analyse • May 11
Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results
As you might know, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) just kicked off its latest quarterly results with some very...
Nouveau récit • May 11
Phase III Trial And Payer Risks Will Shape Dravet Treatment Prospects
Catalysts About Stoke Therapeutics Stoke Therapeutics is a biotechnology company focused on RNA-based medicines, including zorevunersen for Dravet syndrome. What are the underlying business or industry changes driving this perspective?Seeking Alpha • May 01
Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome
Summary I initiate Stoke Therapeutics with a Buy rating, driven by late-stage progress for zorevunersen in SCN1A Dravet Syndrome. STOK's phase 3 EMPEROR trial for zorevunersen targets mid-2027 data and a rolling NDA submission in the first half of 2027. Three-year open-label data show durable seizure reduction and functional improvement, supporting disease-modifying potential for zorevunersen. STOK's $390.9M cash position, Biogen partnership, and low burn rate provide runway into mid-2028, mitigating near-term financing risk. Read the full article on Seeking AlphaArticle d’analyse • Jan 12
Newsflash: Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Have Been Trimming Their Revenue Forecasts
The analysts covering Stoke Therapeutics, Inc. ( NASDAQ:STOK ) delivered a dose of negativity to shareholders today, by...Article d’analyse • Dec 05
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 36% But Its Business Still Trails The Industry
Despite an already strong run, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have been powering on, with a gain of...Article d’analyse • Oct 09
Stoke Therapeutics, Inc. (NASDAQ:STOK) Held Back By Insufficient Growth Even After Shares Climb 39%
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have continued their recent momentum with a 39% gain in the last month...Article d’analyse • Aug 25
Improved Revenues Required Before Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock's 49% Jump Looks Justified
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have continued their recent momentum with a 49% gain in the last month...Article d’analyse • Aug 15
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Could Be 25% Above Their Intrinsic Value Estimate
NasdaqGS:STOK 1 Year Share Price vs Fair Value Explore Stoke Therapeutics's Fair Values from the Community and select...Article d’analyse • May 20
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 28% But Its Business Still Trails The Industry
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders would be excited to see that the share price has had a great...Article d’analyse • Apr 16
Analysts Are More Bearish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Than They Used To Be
Market forces rained on the parade of Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders today, when the analysts...Article d’analyse • Apr 05
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
To the annoyance of some shareholders, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares are down a considerable 27% in...Article d’analyse • Feb 26
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Feb 16
Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer
Summary Stoke Therapeutics' RNA-based treatments for severe neurological and ophthalmic disorders, particularly zorevunersen for Dravet syndrome, show potential for long-term value beyond a single drug. Financials reveal high R&D spending and cash burn, but revenue growth from Acadia Pharmaceuticals collaboration suggests early monetization and potential non-dilutive funding. The Phase 3 EMPEROR study for zorevunersen is critical, with regulatory alignment and promising early data, but execution and long-term safety monitoring remain challenges. Stoke's broader pipeline, including treatments for SYNGAP1-related disorders, Rett syndrome, and Autosomal Dominant Optic Atrophy, could expand its market potential if RNA modulation proves broadly effective. Read the full article on Seeking AlphaArticle d’analyse • Nov 08
Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) just released its third-quarter report and things are looking bullish. Results...Article d’analyse • Nov 06
Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders will have a reason to smile today, with the analysts making...Seeking Alpha • Sep 07
Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome
Summary STOK's zorevunersen shows strong efficacy in reducing seizures but has safety concerns, particularly elevated CSF protein levels, needing further monitoring. Dravet Syndrome market potential is significant, with 35,000 patients in key regions and existing treatments costing up to $96,000 annually. STOK has a solid cash runway for 7-8 quarters, with a Phase 3 trial expected to start soon, aiming for topline data by mid-2026. Despite recent stock gains, I may consider investing when Phase 3 trial enrollment is announced, given the promising genetic approach to Dravet Syndrome. Read the full article on Seeking AlphaArticle d’analyse • Jul 22
We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Jun 14
Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
Summary Stoke Therapeutics' TANGO platform enhances RNA output to compensate for gene mutations causing severe genetic diseases. STOK primarily focuses on developing treatments for Dravet syndrome and autosomal dominant optic atrophy (ADOA). STK-001, a Phase 1/2 candidate for Dravet syndrome, shows promising clinical results with seizure reduction and cognitive improvements. Collaborations with ACAD involve significant milestones and potential royalty payments, enhancing its financial outlook. STOK's financials are strong, with a healthy cash runway and potential for significant royalty revenues, making it a promising investment. Read the full article on Seeking AlphaAnalyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$170m |
| Dec 31 2025 | US$27m | US$171k | -US$7m |
| Sep 30 2025 | n/a | n/a | US$41m |
| Jun 30 2025 | n/a | n/a | US$52m |
| Mar 31 2025 | n/a | n/a | US$50m |
| Dec 31 2024 | US$248k | n/a | -US$89m |
| Sep 30 2024 | n/a | n/a | -US$105m |
| Jun 30 2024 | n/a | n/a | -US$104m |
| Mar 31 2024 | n/a | n/a | -US$109m |
| Dec 31 2023 | US$394k | n/a | -US$105m |
Rémunération vs marché: La rémunération totale de Ian ($USD 27.03M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 5.47M ).
Rémunération et revenus: La rémunération de Ian a augmenté alors que l'entreprise n'est pas rentable.
PDG
Ian Smith (59 yo)
1.2yrs
Titularisation
US$27,031,655
Compensation
Mr. Ian F. Smith, CPA, ACA, is CEO of Stoke Therapeutics, Inc. from October 6, 2025 and serves as its Director since September 19, 2023 and served as its Interim CEO from March 19, 2025 to October 6, 2025....
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Director | 1.2yrs | US$27.03m | pas de données | |
| Co-Founder & Independent Director | no data | US$268.34k | 0.45% $ 8.3m | |
| Chief Financial Officer | 2.1yrs | US$1.83m | 0.016% $ 298.4k | |
| Advisor & Director | 1.2yrs | US$3.23m | 0.18% $ 3.3m | |
| Chief Patient Officer | 2.1yrs | US$2.27m | 0.017% $ 301.5k | |
| Co-Founder | no data | pas de données | pas de données | |
| Director of Communications & Investor Relations | 1.3yrs | pas de données | pas de données | |
| Corporate Secretary & General Counsel | 5.3yrs | pas de données | 0.031% $ 573.4k | |
| Vice President of Corporate Communications | less than a year | pas de données | pas de données | |
| Chief People Officer | 1.3yrs | pas de données | pas de données | |
| Chief Medical Officer | 8.6yrs | US$2.47m | 0.059% $ 1.1m | |
| Chief of Corporate Affairs & Strategic Partnerships | less than a year | pas de données | pas de données |
1.3yrs
Durée moyenne de l'emploi
52yo
Âge moyen
Gestion expérimentée: L'équipe de direction de STOK n'est pas considérée comme expérimentée (ancienneté moyenne 1.3 ans), ce qui suggère une nouvelle équipe.
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Director | 2.7yrs | US$27.03m | pas de données | |
| Co-Founder & Independent Director | 11.9yrs | US$268.34k | 0.45% $ 8.3m | |
| Advisor & Director | 8.6yrs | US$3.23m | 0.18% $ 3.3m | |
| Independent Director | 10.8yrs | US$270.84k | 3.01% $ 55.0m | |
| Independent Director | 10.7yrs | US$281.25k | 0.036% $ 651.8k | |
| Independent Director | 5.8yrs | US$280.84k | 0% $ 0 | |
| Independent Director | 5.9yrs | US$283.34k | 0% $ 0 | |
| Independent Director | 6.9yrs | US$283.34k | 0% $ 0 | |
| Chairman of the Board | 7.7yrs | US$778.78k | 0.050% $ 919.5k | |
| Independent Director | less than a year | pas de données | pas de données |
7.3yrs
Durée moyenne de l'emploi
63.5yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de STOK sont considérés comme expérimentés (ancienneté moyenne 7.3 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/24 16:54 |
| Cours de l'action en fin de journée | 2026/05/22 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Stoke Therapeutics, Inc. est couverte par 21 analystes. 11 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Gregory Harrison | BofA Global Research |
| Thomas Shrader | BTIG |
| Michelle Gilson | Canaccord Genuity |